2020 West Oncology Conference at Graceland

The 5th Annual West Oncology Conference at Graceland: Advances in the Business and Science of Oncology Special Updates from COA, ASCO, ASH, ASTRO, and ESMO was a valuable forum for the presentation and discussion of new research findings. Participants were provided with an update on practice-changing data on women’s cancers, genitourinary malignancies, disparities in cancer care, gastrointestinal cancers, head and neck cancers, and lung cancer in a practical and interactive format, fostering discussion and impacting clinical outcomes for patients. 

Get Started Now

Enroll in Course

Learning Objectives

Identify novel targeted and immunologic approaches to therapy for various cancers

Assess emerging targeted and immunologic therapies

Integrate recent findings on healthcare disparities into optimal therapy selection for individual patients with cancer

Identify optimal therapies for patients and managing and mitigating side effects

Describe the role of nurses and other clinicians in counseling patients with cancer and integrating treatment recommendations to optimize care

Describe findings from recent clinical trials evaluating immunotherapies

Describe the role of nurses and other clinicians in counseling patients with cancer and integrating treatment recommendations to optimize care

Identify strategies to prevent and manage the treatment-related adverse events of targeted therapies and immunotherapies to improve tolerability and maintain quality of life

Accreditation Information

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 12.50 AMA PRA Category 1 CreditsTM for physicians and 12.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity

 

How This Course Works

This course consists of pre-recorded sessions that took place at the 2020 West Oncology Conference at Graceland on February 28-29, 2020.  

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

A link to the evaluation will be provided at the conclusion of the course.

If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.

 

Frequently Asked Questions

How do I access my CME/CE Credits?

A link will be provided you to you at the conclusion of the course. You will be asked to fill out a brief evaluation and your certificate will be automatically emailed back to you.

How long do I have access to the course?

This CME course will be available to access until April 16, 2023.

Can I have face to face interaction with Instructor?

No, this is an online self-paced course with video demonstration. However, you are free to connect with the medical experts for each session on social media or contact the team and we will connect you. 

How many credits can I obtain?

Amedco LLC designates this enduring activity for a maximum of 12.50 AMA PRA Category 1 CreditsTM for physicians and 12.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity

Course Curriculum

  • 2020 West Oncology Learners Notification
    5 minutes
  • Treatment of 42 y/o With Grade 3 Invasive Ductal Carcinoma, ER/PR -, HER2+: Breast MRI, Biopsy of Left Axillary LN’s, Neoadjuvant Therapy With TCHP
    13 minutes
  • Treatment of 42 y/o with HER2+ Breast Cancer, T1b Lesions and Positive Lymph Nodes: Managing Axilla, Radiation, Residual Cancer Burden & Additional Systemic Therapy With TDM1
    20 minutes
  • Treatment of Metastatic HER2+ Breast Cancer: Radiation Strategy for Newly Diagnosed Brain Mets, 1st Line Systemic Therapy & Approach for Additional Brain Mets Found On Routine Restaging
    15 minutes
  • Immunotherapy in NSCLC: Progression, irAE management & Combination Therapies
    15 minutes
  • Update on Early Stage NSCLC: Role of Screening, Neoadjuvant Therapies (Immune Checkpoint Inhibitors, Neo Chemo/IO) & Durvalumab in Surgically Unresectable Stage III
    15 minutes
  • Use of Stereotactic Radiation for NSCLC Pts & Vale of IO after SBRT
    10 minutes
  • New RT Approaches to Stage III NSCLC Pts: Can Radiotherapy Be Further Improved? & Ultra-High Dose Rate Radiation
    9 minutes
  • Management of 2nd Line EGFR + NSCLC: Post Osimertinib Resistance, Use of Novel Bispecific Antibody Targeting cMET, Safety Data of IO Concerning, Use of Anti-angiogenesis
    10 minutes
  • 2020 Update on NSCLC Targeted Therapies: ALK, ROS1, RET, MET, NTRK, KRAS and BRAF
    10 minutes
  • Personalized First-line Therapy for mCRC: FOLFOX + BEV Should Not Be Considered the One-size-fits-all SOC & Drug Approvals Based on Molecular Signature Are Emerging
    17 minutes
  • Colorectal Cancer: Novel Biomarkers for Decision Making in Adjuvant Setting, Immunoscore, ctDNA and MRD Testing
    20 minutes
  • Rectal Cancer Treatment: Pre-operative vs Postoperative RT, Short and Long Course ChemoRT Approach, & Total Neoadjuvant Therapy
    19 minutes
  • Surgical Management of Colorectal Liver Metastases: Selection of Pts for Hepatic Resection, Criteria for Resectability, Chemo Induced Liver Injury & Importance of Multidisciplinary Coordination
    20 minutes
  • Current Landscape of Molecular Testing in Prostate Cancer: Which Test, When to Test, and What Do I Do With It?
    23 minutes
  • Non-Muscle Invasive Bladder Cancer, Pembro Approval and New agents Oportuzumab Monatox and Nadofaragene Firadenovec
    7 minutes
  • Management of Metastatic Urothelial Cancer: Prognostic Value of ctDNA Detection, Trials of Anti-PD-1/ PD-L1, Targeting FGFR Inhibitors & New Approaches with Antibody-Drug Conjugates
    15 minutes
  • Treatment of 63 y/o Male with Stage 4 Urothelial Cancer: 2nd Systemic Treatment with Pembro & Subsequent Therapy with Enfortumab Vedotin
    8 minutes
  • Erdafitinib Treatment of 77 y/o Female With Metastatic Urothelial Cancer
    9 minutes
  • Treatment Options for Newly Diagnosed Myeloma: Time to Incorporate CD38 Antibodies?
    12 minutes
  • Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the Myriad Of Choices
    9 minutes
  • Future Directions in Multiple Myeloma: Selinexor Approval, Venetoclax, Belantamab Mafodotin, BCMA:CD3 Bispecifics & CAR T
    12 minutes
  • Frontline Therapy in CLL: Obinutuzumab + Ibrutinib, Ibrutinib vs. Chemoimmunotherapy, Alternative BTK and Related AEs
    14 minutes
  • Time Limited Therapy in CLL, Ibrutinib vs Zanubrutinib in WM & LOXO-305 in B-cell Malignancies
    18 minutes
  • History and Current Status of Community Oncology
    19 minutes
  • Innovation and Evolution of Community Oncology: Value Based Care, OneOncology, Precision Oncology & Regimen Standardization
    20 minutes
  • Payment Models and Reform in Oncology: Alternative Payment Models, Medicare, Oncology Care Model
    30 minutes
  • Improving Care: ASCO’s Patient-Centered Oncology Payment Model
    10 minutes
  • How Community Oncology Is Shaping the Future of Cancer Care – Importance of Clinical Trials
    28 minutes
  • Healthcare Trends and Challenges Facing Community Oncology
    11 minutes
  • The Shift from Fee for Service to Value-based Care in Oncology: Care Delivery Models
    18 minutes
  • How to Prepare for Value-based Care With Focus on OneOncology
    10 minutes
  • How We Can Prosper and Get Ahead in the Current Community Healthcare Landscape?
    8 minutes
  • Maximizing APP Productivity and Barriers to Successful Practice & Integration of the APPs Into the Team
    12 minutes
  • Functions of the Advanced Practice Provider in Oncology, Importance of Team-based Care & Methods of Integrating APPs Into the Practice
    18 minutes
  • Preventing Burnout: Symptoms, Risk Factors, Strategies to Help Combat Burnout
    25 minutes
  • Intersection Between Survivorship & Palliative Care and Integration in Oncology Practice
    27 minutes
  • Encouraging Work-Life Balance
    17 minutes
  • Discussion on Use of Biosimilars in Clinical Practice, IO Approaches and PDL-1 Testing
    27 minutes

Get Started Now

Enroll in Course